Comparisons10 min readUpdated 2026-05-04

    Compounded Semaglutide vs Wegovy 2026: $99/mo vs $1,400/mo (Same Active Ingredient)

    Honest comparison of compounded semaglutide vs Wegovy in 2026 — same active ingredient, dramatically different price. When to choose each, and how to save 90%+ legitimately.

    Quick Verdict

    Compounded semaglutide and Wegovy contain the same active ingredient (semaglutide). The difference is regulatory pathway: Wegovy is FDA brand-name; compounded semaglutide is FDA 503A/503B pathway. Both are legitimate.

    Cost difference: Trimi's compounded semaglutide is $99/mo flat; cash-pay Wegovy is $1,200-$1,400/mo retail or ~$499/mo via NovoCare. Annual savings switching to compounded: $4,800-$15,612/year.

    About this comparison

    Both compounded semaglutide and Wegovy are legitimate medical products. Wegovy is FDA-approved as a brand-name medication by Novo Nordisk; compounded semaglutide is dispensed by FDA 503A/503B pharmacies under federal and state oversight. Pricing is based on publicly listed rates as of May 2026. This article is informational and not medical advice.

    Side-by-Side Comparison

    FactorWegovyCompounded Semaglutide (Trimi)
    Active ingredientSemaglutideSemaglutide (identical)
    Regulatory pathwayFDA brand-name approvalFDA 503A / 503B compounding
    ManufacturerNovo Nordisk (FDA-approved facilities)Licensed 503A/503B compounding pharmacy
    Cash price (monthly)$1,200-$1,400/mo retail; ~$499/mo NovoCare$99/mo flat
    Annual cash cost$5,988-$16,800/yr$1,188/yr
    Insurance coverageVariable (employer-dependent for weight loss)N/A — cash-pay model
    Delivery systemPre-filled pens (or vials via NovoCare)Vials with syringes (typically)
    Provider modelStandard prescription via PCP/specialistTelehealth provider with 10-15 min intake
    Speed: prescription → medicationSame-day pickup at pharmacy5-10 days from intake to delivery

    The Math: 12-Month Cost Comparison

    For a typical patient on semaglutide for 12 months:

    Wegovy (retail)

    $14,400-$16,800

    $1,200-$1,400/mo × 12

    Wegovy (NovoCare)

    $5,988

    ~$499/mo × 12 (vials)

    Trimi (compounded)

    $1,188

    $99/mo × 12 (flat)

    Annual savings switching from Wegovy retail to compounded: $13,212-$15,612

    Annual savings switching from NovoCare to compounded: $4,800

    Where Wegovy Wins

    Wegovy's genuine strengths over compounded semaglutide:

    • FDA brand-name approval: Full pharmacokinetic studies, uniform manufacturing in Novo Nordisk facilities, complete prescribing information for weight management
    • Pre-filled pen delivery: Simpler administration than vials + syringes (especially for needle-averse patients) — though NovoCare uses vials
    • Insurance coverage path: Some employer plans cover Wegovy; compounded options aren't typically covered
    • Same-day pharmacy access: Pick up at CVS/Walgreens immediately after prescription; compounded ships in 5-10 days
    • Established product reputation: Patients and providers familiar with the brand
    • Long track record: Semaglutide has been on the market longer than tirzepatide; Wegovy specifically has years of post-market data

    Where Compounded Semaglutide Wins

    Compounded semaglutide's genuine strengths over Wegovy:

    • Cost: 92-93% cheaper than retail; 80% cheaper than NovoCare — $4,800-$15,612 saved annually
    • Same active ingredient: Semaglutide is the molecule responsible for weight loss — both products contain it identically
    • Telehealth convenience: 10-15 minute online intake from home; no in-person visits, no pharmacy queue
    • Provider specialization: Compounded telehealth providers (like Trimi) focus exclusively on GLP-1 medications
    • No insurance hoops: Flat pricing bypasses prior authorization, formulary games, copay surprises
    • Predictable monthly cost: $99/month every month, no insurance changes affecting your treatment

    When Wegovy Is the Right Choice

    Wegovy is the better pick if:

    • Your insurance covers Wegovy and the copay is $50/month or less
    • You qualify for the Wegovy Savings Card and the discounted price beats compounded options
    • You strongly prefer pen delivery over vial + syringe
    • You want same-day pharmacy pickup (compounded ships in 5-10 days)
    • You have specific medical reasons where uniform brand-name manufacturing matters

    When Compounded Semaglutide Is the Right Choice

    Compounded semaglutide is the better pick if:

    • You're paying cash and don't have insurance coverage for Wegovy
    • You don't qualify for the Wegovy Savings Card or NovoCare's self-pay program
    • Cost is a meaningful factor — $13,200+/year savings is substantial over multiple years of treatment
    • You prefer telehealth convenience (online intake, home delivery)
    • You're comfortable with vials + syringes for administration
    • You're comfortable with the FDA 503A/503B compounding pathway as legitimate medical option

    How to Switch from Wegovy to Compounded Semaglutide

    1. 1
      Don't run out of Wegovy first: Time the transition so you have a 1-2 week supply in hand when starting Trimi's intake.
    2. 2
      Submit Trimi's intake: 10-15 minute online questionnaire, including your current Wegovy dose, titration history, and any side effects.
    3. 3
      Provider review: Trimi's licensed clinician reviews your history (24-48 hours) and prescribes compounded semaglutide at your existing dose.
    4. 4
      Medication ships: 3-5 business days to your home from a licensed compounding pharmacy.
    5. 5
      Continue treatment: Weekly injection at the same dose. Your titration schedule, weight loss progression, and side effect profile should remain consistent.

    Frequently Asked Questions

    Is compounded semaglutide the same drug as Wegovy?

    Yes — both contain semaglutide as the active ingredient. The molecule is identical. The difference is the regulatory pathway: Wegovy is FDA-approved as a brand-name medication manufactured by Novo Nordisk; compounded semaglutide is dispensed by FDA 503A or 503B compounding pharmacies. Same drug, different production.

    How much cheaper is compounded semaglutide vs Wegovy?

    Dramatically cheaper. Compounded semaglutide via Trimi is $99/month flat ($1,188/year). Wegovy at retail pharmacy is $1,200-$1,400/month ($14,400-$16,800/year). NovoCare's self-pay program is ~$499/month ($5,988/year). Trimi saves 80-93% versus brand-name pricing.

    Is compounded semaglutide as effective as Wegovy?

    Real-world outcomes data (when available) suggests similar weight loss results. The active ingredient is identical, so effectiveness should be comparable for most patients. Brand-name Wegovy has the advantage of pharmacokinetic studies and uniform manufacturing controls. Compounded versions from licensed 503A/503B pharmacies use the same active ingredient with rigorous quality testing.

    Is compounded semaglutide legal?

    Yes. Compounded semaglutide is dispensed under FDA 503A and 503B pathways — established compounding regulations that have existed for decades. During FDA's semaglutide shortage declaration (2022-2024), compounding was explicitly permitted to ensure patient access. Outside of shortage status, FDA 503A and 503B pathways allow compounding for clinically necessary patient-specific prescriptions and bulk compounding for healthcare facilities.

    Why does Wegovy cost so much more?

    Brand-name pharmaceutical pricing reflects R&D recovery, FDA-approved manufacturing facilities, marketing investment, and what the U.S. healthcare market will bear during patent protection. Compounded versions use the same active ingredient but bypass brand-name marketing, sales force, and patent-recovery pricing.

    Can I switch from Wegovy to compounded semaglutide?

    Yes — many patients do, primarily for cost reasons. The active ingredient is the same, so dose and titration schedule transfer directly. Request your prescription history from your Wegovy prescriber, then submit Trimi's 10-15 minute online intake. Trimi providers can continue treatment at your current dose.

    Is Wegovy or Ozempic the right comparison?

    Both Wegovy and Ozempic contain semaglutide. Wegovy is FDA-approved for weight loss; Ozempic is FDA-approved for type 2 diabetes. The active ingredient is identical. If you're using either brand for weight loss and looking for compounded alternatives, the comparison applies equally — compounded semaglutide is the same molecule at much lower cost.

    Disclaimer: Wegovy is a registered trademark of Novo Nordisk. Trimi is an unaffiliated telehealth provider offering compounded semaglutide. Both are legitimate medical products under different regulatory pathways. Pricing is current as of May 2026 and subject to change. This article is informational and not medical advice. Always consult a licensed clinician about whether semaglutide (brand-name or compounded) is appropriate for your individual health situation.

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 4, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Compare Wegovy and compounded semaglutide side by side: pricing, effectiveness, safety, and availability in 2026. Find out which option saves you more without sacrificing quality.

    Ozempic vs compounded semaglutide: compare cost, effectiveness, side effects, and availability in 2026. Learn why most patients choose compounded and save thousands.

    Honest comparison of compounded tirzepatide vs Zepbound in 2026 — same active ingredient, dramatically different price. When to choose each, and how to save 88%+ legitimately.

    Mochi Health semaglutide costs $178/month ($79 membership + $99 medication). Compare dosing, delivery, sublingual vs injectable options, and why Trimi delivers equivalent care at $99/month all-in.

    Start your GLP-1 journey — from $99/mo

    Get Started